Evidence map›Paper›PMID 42485649›Full record

ArticleThe New England journal of medicine2026

Cross-Reactive Bundibugyo Antibody Responses after Receipt of Licensed Ebola Vaccines.

Edouard Lhomme, Aurélie Wiedemann, Ahidjo Ayouba, Safaa Ben-Farhat, Guillaume Thaurignac, Céline Roy, Abdoul Habib Beavogui, Seydou Doumbia, Mark Kieh, Bailah Leigh and 9 more

Abstract readLetter
PubMed Publisher
In one paragraph

Article in The New England journal of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors.

Edouard LhommeUniversité de Bordeaux, Bordeaux, France.
Aurélie WiedemannUniversité Paris Est Créteil, Créteil, France.ORCID 0000-0002-4224-3137
Ahidjo AyoubaInstitut de Recherche pour le Développement, Montpellier, France.
Safaa Ben-FarhatINSERM, Bordeaux, France.
Guillaume ThaurignacInstitut de Recherche pour le Développement, Montpellier, France.
Céline RoyINSERM, Bordeaux, France.
Abdoul Habib BeavoguiCentre National de Formation et de Recherche en Santé Rurale de Maferinyah, Maferinyah, Guinea.
Seydou DoumbiaUniversity Clinical Research Center, Bamako, Mali.
Mark KiehPartnership for Research on Ebola Virus in Liberia (PREVAIL), Monrovia, Liberia.
Bailah LeighUniversity of Sierra Leone, Freetown, Sierra Leone.
Samba SowUniversity of Maryland School of Medicine, Baltimore.
Stephen A MiguelesNational Institute of Allergy and Infectious Diseases, Bethesda, MD.
Deborah Watson-JonesLondon School of Hygiene and Tropical Medicine, London.
Yazdan YazdanpanahAssistance Publique-Hôpitaux de Paris, Paris.
Rodolphe ThiébautUniversité de Bordeaux, Bordeaux, France.
Martine PeetersInstitut de Recherche pour le Développement, Montpellier, France.
Laura RichertUniversité de Bordeaux, Bordeaux, France.
Yves LevyUniversité Paris Est Créteil, Créteil, France.
PREVAC Study Team

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
European Commission RIA2017S-2014 - PREVAC-UPInnovative Medicines Initiative 115854 EBOVAC1NCI NIH HHS 75N91019D00024NCI NIH HHS HHSN261201500003I
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42485649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.